Trial reportInternational journal of pancreatology : official journal of the International Association of Pancreatology1997
Cytokeratin 19 fragment in serum and tissues of patients with pancreatic diseases.
Trial report in International journal of pancreatology : official journal of the International Association of Pancreatology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- Article
- Immunotherapy for Lewis lung carcinoma utilizing dendritic cells infected with CK19 gene recombinant adenoviral vectors.Oncology reports · 2015Article
- Cutaneous metastases of pancreatic carcinoma as a first clinical manifestation.The Korean journal of internal medicine · 2005Article
- Immunoglobulin A secretion into pancreatic juice as a novel marker of local immune defense and exocrine pancreatic function.Digestive diseases and sciences · 2001Article
- Detection of extrapancreatic nerve plexus invasion of pancreatic adenocarcinoma. Cytokeratin 19 staining and K-ras mutation.International journal of pancreatology : official journal of the International Association of Pancreatology · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
conclusionThe present study has shown that increased serum levels of cytokeratin 19 fragment reflect increases in the size of the pancreatic carcinomas, although the sensitivity for detecting small pancreatic carcinomas was low.
backgroundCytokeratin is a member of the intermediate family of filaments in epithelial cells. The cytokeratin 19 fragment is an acidic cytokeratin, which is found in various epithelial tissues. Recently, the serum fragment of cytokeratin 19 has been measured and found to be a good marker for squamous cell carcinoma. Cytokeratin 19 is known to be expressed in normal pancreatic tissues and pancreatic carcinomas. However, serum cytokeratin 19 levels in pancreatic diseases have not been precisely detailed.
methodsIn this study, we evaluated serum cytokeratin 19 levels and the immunohistochemical expression of cytokeratin 19 in various pancreatic diseases.
resultsSerum cytokeratin 19 levels were high (> 2 ng/mL) in 51 of 99 (52%) cases of pancreatic duct cell carcinoma, but were low in all 24 cases of chronic pancreatitis and in 7 cases of islet cell tumors. The sensitivity of the cytokeratin 19 assay increased with increased size of the pancreatic carcinomas, but was not influenced by the presence of obstructive jaundice. Immunohistochemical studies using a monoclonal anticytokeratin 19 antibody showed that staining for cytokeratin was positive in all 38 of the pancreatic carcinomas examined and in 2 of 6 islet tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.